Principal Securities’s Verve Therapeutics VERV Stock Holding History

Principal Securities’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-188	Closed	-$2.11K	–	3853
2025 Q2	$2.11K	Sell	188 -58	-24%	-$331	﹤0.01%	3132
2025 Q1	$1.39K	Hold	246	–	–	﹤0.01%	3137
2024 Q4	$1.39K	Hold	246	–	–	﹤0.01%	3131
2024 Q3	$1.19K	Buy	246 +80	+48%	+$465	﹤0.01%	3097
2024 Q2	$810	Sell	166 -32	-16%	-$201	﹤0.01%	3111
2024 Q1	$2.63K	Sell	198 -55	-22%	-$729	﹤0.01%	2797
2023 Q4	$3.53K	Buy	+253	New	+$3.14K	﹤0.01%	2656

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Principal Securities's VERV Position: Q3 2025 in Review

Principal Securities sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 188 shares — an estimated $2.11K sold.

Principal Securities first reported a position in VERV in Q4 2023 and held it in 7 quarters. The position peaked at $3.53K in Q4 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Principal Securities reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Principal Securities sold 188 Verve Therapeutics shares in Q3 2025, an estimated $2.11K.
Principal Securities first reported a position in Verve Therapeutics in Q4 2023 and held it in 7 quarters.
Principal Securities's Verve Therapeutics position peaked at $3.53K in Q4 2023.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Principal Securities's 13F filing for Q3 2025, filed 12 Nov 2025.